Key facts
- Juro Sciences’s last known valuation is $19.6M (Sep 2025).
- It has raised $8.3M; the latest was Early Stage VC ($6.1M) in Sep 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, FFG Venture Business Partners, Gemseki, Miyako Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Juro Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Juro Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juro Sciences
Developer of a biotech platform designed to deliver medicines for an underactive bladder. The company's platform combines novel drug delivery systems and targeted therapeutic mechanisms to minimize side effects and maximize efficacy, enabling doctors to improve symptoms and improve quality of life for patients suffering from UAB.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2021
- Employees
- 4
- Website
- jurosci.com/
- Ownership
- Privately Held (backing)
Juro Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juro Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juro Sciences in its N-PORT filings yet. We sweep new filings monthly.